Lundberg Sven Ante 4

What Happened

• Sven Ante Lundberg, a director of Q32 Bio, received a grant of stock options on 2026-01-15. The award covers 20,363 option shares with a $2.75 exercise price, listed in the filing with a value of $55,998. This was an award of derivative securities (options), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-15; Filing date: 2026-01-30 (filed late).
• Instrument: Stock option grant (derivative); 20,363 options granted at a $2.75 strike price; reported value $55,998.
• Vesting: The options vest in four equal quarterly installments on the last day of each calendar quarter, subject to continued service.
• Purpose: The award represents the director’s election to receive options in lieu of cash retainer fees under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.
• Filing timeliness: Marked late — footnote says the award initially was not reported due to administrative oversight.

Context

• This was an option grant (award), not an exercise or sale. Options vest over time and must be exercised to convert into shares, so this does not represent immediate share purchases or sales.
• Awards to directors as compensation are common and do not necessarily indicate buying or selling intent by the insider. The late filing reduces near-term transparency but the footnote explains it as administrative oversight.